SGLT2 inhibitors are highly effective medications for the treatment of diabetes mellitus, chronic heart failure, and chronic kidney disease. They improve key clinical outcomes and are therefore strongly recommended by national and international guidelines. However, in addition to their benefits, SGLT2 inhibitors also carry risks. A rare but serious side effect is SGLT2 inhibitor-associated ketoacidosis, which can occur even when blood glucose levels are within the normal range and poses a diagnostic challenge. In the context of surgery, factors such as fasting, stress, and inflammation could increase this risk. Therefore, current guidelines recommend discontinuing these medications approximately 72 hours before surgery. However, this recommendation is based on limited evidence.
Meanwhile, recent studies show that ketoacidosis can still occur despite discontinuation in accordance with guidelines. Data from large retrospective registry studies also suggest that SGLT2 inhibitors may have organ-protective effects during the perioperative period and could reduce postoperative mortality.
In summary, there is considerable uncertainty regarding the correct perioperative management of SGLT2 inhibitors.
This presentation will review the current evidence on this topic and place it within the perioperative context. The speaker is Dr. Sebastian Roth of the University Hospital in Essen.
Registration is available online.